Guideline for wireless capsule endoscopy in children and adolescents: A consensus document by the SEGHNP (Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition) and the SEPD (Spanish Society for Digestive Diseases)

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Arguelles-Arias, F
  • Fernandez-Urien, I
  • Alberce, F
  • Arguelles-Martin, F
  • Martinez, MJ
  • Molina, M
  • Varea, V
  • Herrerias-Gutierrez, JM

Grups d'Investigació

Abstract

INTRODUCTION: Capsule Endoscopy (CE) in children has limitations based mainly on age. The objective of this consensus was reviewing the scientific evidence. MATERIAL AND METHODS: Some experts from the Spanish Society of Gastroenterology (SEPD) and Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition (SEGHNP) were invited to answer different issues about CE in children. These sections were: a) Indications, contraindications and limitations; b) efficacy of CE in different clinical scenarios; c) CE performance; d) CE-related complications; e) Patency Capsule; and f) colon capsule endoscopy. They reviewed relevant questions on each topic. RESULTS: The main indication is Crohn's disease (CD). There is no contraindication for the age and in the event that the patient not to swallow it, it should be administered under deep sedation with endoscopy and specific device. The CE is useful in CD, for the management of OGIB in children and in Peutz-Jeghers syndrome (in this indication has the most effectiveness). The main complication is retention, which should be specially taken into account in cases of CD already diagnosed with malnutrition. A preparation regimen based on a low volume of polyethylene glycol (PEG) the day before plus simethicone on the same day is the best one in terms of cleanliness although does not improve the results of the CE procedure. CONCLUSIONS: CE is safe and useful in children. Indications are similar to those of adults, the main one is CD to establish both a diagnosis and disease extension. Moreover, only few limitations are detected in children.

Dades de la publicació

ISSN/ISSNe:
1130-0108, 2340-4167

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS  ARAN EDICIONES, S A

Tipus:
Article
Pàgines:
714-731
DOI:
PubMed:
26671584
Factor d'Impacte:
0,377 SCImago
Quartil:
Q3 SCImago

Cites Rebudes en Web of Science: 22

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Capsule endoscopy; Children; Guideline; Spanish Society for Digestive Diseases; Spanish Society for Pediatric Gatroenterology, Hepatology and Nutrition

Campos d'Estudi

Projectes associats

ANALISIS DE NUEVOS GENES IMPLICADOS EN LA PATOGENESIS DE LA ENFERMEDAD CELIACA

Investigador Principal: CARMEN RIBES KONINCKX

PI02/0573 . INSTITUTO DE SALUD CARLOS III . 2004

INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP

Investigador Principal: CARMEN RIBES KONINCKX

643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015

NUEVA ESTRATEGIA PARA LA DERIVACIÓN DE HEPATOCITOS FUNCIONALES DE MUJERES AFECTAS DE DEFICIENCIA DE ORNITINA TRANSCARBAMILASA

Investigador Principal: BERNARDO ROQUE BORT MARTÍ

SAF2014-51991-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2015

UN REGISTRO NO INTERVENCIONISTA A LARGO PLAZO PARA EVALUAR LA SEGURIDAD Y EFECTIVIDAD DE HUMIRA® (ADALIMUMAB) EN PACIENTES PEDIÁTRICOS CON ENFERMEDAD DE CROHN (EDC) ACTIVA ENTRE MODERADA Y GRAVE (CAPE).

Investigador Principal: ESTHER DONAT ALIAGA

P11-292 . 2015

ESTUDIO ABIERTO, MULTICÉNTRICO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE OMBITASVIR (OBV), PARITAPREVIR (PTV), RITONAVIR (RTV), CON O SIN DASABUVIR (DSV) Y CON O SIN RIBAVIRINA (RBV) EN PACIENTES PEDIÁTRICOS CON INFECCIÓN CRÓNICA POR EL VIRUS DE LA HEPATITIS C (VHC) GENOTIPO 1 O 4 (ZIRCON).

Investigador Principal: CARMEN RIBES KONINCKX

M14-748 . 2016

ESTUDIO DE SEGURIDAD Y CAPACIDAD NUTRICIONAL DE UNA NUEVA FORMULA HIPOALERGICA PARA LACTANTES CON DIVERSAS FORMAS DE ALERGIA A LAS PROTEINAS DE LA LECHE DE VACA.

Investigador Principal: CARMEN RIBES KONINCKX

HER-FHT-2009-01 . 2010

A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 YEARS TO < 18 YEARS WITH FUNCTIONAL CONSTIPATION. / ESTUDIO MULTICENTRICO, ALEATORIZADO, CONTR OLADO CON PLACEBO Y CON DOBLE ANONIMATO (DOBLE CIEGO) DE LA EFICACIA, SEGURIDAD Y FARMACOCINETICA DE LA LUBIPROSTONA EN PACIENTES PEDIATRICOS CON EDAD . 6 ANOS Y < 18 ANOS CON ESTRENIMIENTO FUNCIONAL.

Investigador Principal: CARMEN RIBES KONINCKX

SAG/0211PFC-1131

A MULTICENTRE, LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS STUDY OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 TO <18 YEARS WITH FUNCTIONAL CONSTIPATION./ ESTUDIO MULTICÉNTRICO A LARGO PLAZO SOBRE LA SEGURIDAD, LA EFICACIA Y LA FARMACOCINÉTICA DE L UBIPROSTONA EN PACIENTES PEDIÁTRICOS DE EDADES COMPRENDIDAS ENTRE >= 6 AÑOS Y < 18 AÑOS CON ESTREÑIMIENTO FUNCIONAL.

Investigador Principal: CARMEN RIBES KONINCKX

SAG/0211PFC-11S1 . 2015

ESTUDIO FARMACOEPIDEMIOLÓGICO PARA ESTABLECER EL PERFIL DE SEGURIDAD A LARGO PLAZO DE TENOFOVIR DISOPROXIL FUMARATO (TENOFOVIR DF, VIREAD®) Y DESCRIBIR EL TRATAMIENTO DE LA TOXICIDAD RENAL Y ÓSEA ASOCIADA A TENOFOVIR DF EN ADOLESCENTES DE 12 A <18 AÑOS CO N HEPATITIS B CRÓNICA (HBC) EN EUROPA.

Investigador Principal: CARMEN RIBES KONINCKX

GS-EU-174-1403 . 2015

Compartir la publicació